SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Globe Newswire•06/10/2026•07:30 ET
0
Key Highlights
- ➤SCY-770 well tolerated across all Phase 1 cohorts, including higher-dose regimens
- ➤Phase 2 ADPKD proof-of-concept study remains on track for fourth-quarter 2026 initiation
- ➤Phase 1 enrolled 25 healthy participants across three dosing cohorts
- ➤SCY-770 safety and tolerability characterized across approximately 300 participants to date
- ➤SCY-770 received FDA Orphan Drug Designation for ADPKD
Expert Statements
Todd Minga, SVP of Research and Development at SCYNEXIS
“We continue to make strong progress toward initiating our Phase 2 study of SCY-770 in patients with ADPKD, and the additional pharmacokinetic and safety data generated in this Phase 1 study provide important insights to support dose selection”
Todd Minga, SVP of Research and Development at SCYNEXIS
“We are encouraged by the favorable safety and tolerability profile observed across the doses studied, which supports continued clinical development of SCY-770. Patients living with ADPKD face a significant unmet medical need, as treatment options remain limited. We look forward to advancing this novel, highly selective oral direct AMPK activator, which has the potential to offer a differentiated therapeutic approach and provide meaningful clinical benefit for patients with this progressive disease.”
• SCY-770 was well tolerated with a favorable safety profile in healthy adult participants at higher doses than previously evaluated
• Phase 2 proof-of-concept study in patients with ADPKD remains on-track to initiate in the fourth quarter of 2026
Get started
Create a free account to read the full story.